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Butyl p-hydroxybenzoic acid, also known as butylparaben (BP), is one of the most common parabens absorbed by the 
skin and gastrointestinal tract and metabolised in the liver and kidney. Recent in vivo and in vitro studies have raised 
concern that BP causes reproductive, development, and teratogenic toxicity. However, BP-induced oxidative stress and 
its relation to tissue damage has not been widely investigated before. Therefore, we aimed to investigate the effects of 
butyl 4-hydroxybenzoate on enzyme activities related to the pentose phosphate pathway and on glutathione-dependent 
enzymes such as glucose 6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (6-PGD), glutathione 
reductase (GR), glutathione peroxidase (GPx), and glutathione-S-transferase (GST) in kidney, liver, brain, and testis 
tissues. Male rats were randomly divided into four groups to orally receive corn oil (control) or 200, 400, or 800 mg/kg/
day of BP for 14 days. Then we measured G6PD, GR, GST, 6-PGD, and GPx enzyme activities in these tissues and studied 
histopathological changes. BP treatment caused imbalance in antioxidant enzyme activities and tissue damage in the liver, 
kidney, brain, and testis. These findings are the first to show the degenerative role of BP on the cellular level. The observed 
impairment of equivalent homeostasis and antioxidant defence points to oxidative stress as a mechanism behind tissue 
damage caused by BP.
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Butylparaben (butyl 4-hydroxybenzoate, BP) from the 
paraben family has widely been used as antimicrobial/
antifungal preservative in cosmetic products, deodorants, 
toiletries, face creams, pharmaceuticals, toys, food, and 
beverages for more than 50 years (1, 2). Parabens are 
endocrine disruptors which impair natural metabolism of 
hormones by mimicking, interfering, and/or blocking them 
(3–6).
After exposure through skin, ingestion, or inhalation, 
BP is metabolised by the liver, kidney, and skin esterases. 
Conjugated forms of BP are excreted in the urine and bile 
in humans, but some of it remains unchanged and 
accumulates in the body over time (2, 7–9). This 
accumulation raises health concerns, as paraben has been 
reported for oestrogen-like activity, endocrine disruption, 
and impairment of the reproductive system. Parabens are 
also closely associated with carcinogenesis, obesity, 
diabetes, inflammatory diseases, and neurodegenerative 
disorders (10–15).
Molecular mechanisms behind this association remain 
unclear, but some studies have shown that endocrine 
disrupting chemicals can damage tissue through oxidative 
imbalance that results in the damage of lipids, DNA, and 
proteins, which in turn triggers the development of a number 
of diseases (16, 17).
Antioxidant enzymes 6-phosphate dehydrogenase 
(G6PD), 6-phosphogluconate dehydrogenase (6-PGD), 
glutathione-S-transferase (GST), glutathione peroxidase 
(GPx), and glutathione reductase (GR) have a vital role in 
reductive biosynthesis and cellular detoxification from free 
radicals and chemicals to help the organism deal with 
internal and external stress (4, 18). GST, GR, and GPx are 
glutathione-dependent antioxidant enzymes, whereas G6PD 
and 6-PGD are glutathione-independent. G6PD is the rate-
limiting enzyme in the pentose phosphate pathway (PPP) 
that maintains the cytosolic NADPH pool involved in 
cellular redox balance (19, 20). 6-PGD is another enzyme 
in the PPP pathway responsible for NADPH production. 
Their impairment is closely associated with elevated 
reactive oxygen species (ROS) in several diseases, including 
cancer, diabetes, inflammatory diseases, and obesity (16, 
17, 21, 22). Reduced glutathione (GSH) is mainly 
responsible for the protection of cells against ROS and it 
is required as cofactor for glutathione dependent enzymes 
(23, 24).
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There are but a few studies on BP-induced oxidative 
stress in mice liver (25), human spermatozoa (26), and rat 
testis (27). None of them, however, reported BP-induced 
oxidative stress and tissue damage in the liver, kidney, or 
brain. Therefore, the aim of our study was to expand 
research of oxidative stress to these organs and histologically 
verify kidney, liver, brain, and testis tissue damage through 
oxidative stress as the mechanism behind BP, which may 
cause a number of abnormalities and diseases.
MATERIALS AND METHODS
Materials
Oxidised glutathione (GSSG), 6-phosphogluconate 
(6-PG), glucose-6-phosphate (G6P), nicotinamide adenine 
dinucleotide phosphate (NADP+), reduced nicotinamide 
adenine dinucleotide phosphate (NADPH + H+), magnesium 
chloride (MgCl2), butylparaben (butyl 4-hydroxybenzoate, 
>99 % purity), sodium phosphate monobasic and dibasic, 
tris, glutathione reductase (GR), hydrogen peroxide (H2O2), 
ethylenediaminetetraacetic acid (EDTA), cOmplete™ 
Protease Inhibitor Cocktail, and sodium azide were obtained 
from Sigma-Aldrich (St. Louis, MO, USA). Alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), 
urea, albumin, triglyceride, creatinine, and glucose kits for 
biochemical analysis were obtained from Audit Diagnostics 
(Cork, Ireland).
Animal care and dose administration
Male Wistar albino rats (Rattus norvegicus) were 
purchased from the Experimental Animals Production 
Center of Hacettepe University (Ankara, Turkey) at six 
weeks of age. We used 24 rats weighing 140–180 g. All 
were housed in polycarbonate cages with stainless steel 
covers in an air-conditioned room (12 h light/dark cycle 
with a temperature of 22 ± 2 °C and relative humidity of 
50±5 %). The animals were acclimated to the laboratory 
for one week before the experiments. During the 14-day 
BP administration, they had free access to tap water and 
standard rat pellet food (Korkutelim Feed Factory, Afyon, 
Turkey). All experimental procedures and animal use were 
approved by the Ethics Committee of Hacettepe University 
(B.30.2.HAC.0.05.0.6.00/132).
The value of low observed toxic effects (LOEL) for 
butylparaben is 1600 mg/kg/day (28). In our study, we 
selected halft the LOEL for our highest daily dose of 
800 mg/kg, and halved it further to 400 and 200 mg/kg/day. 
The rats were randomly divided into four groups of six to 
receive oil vehicle only (control) or 200, 400 or 800 mg/kg 
per day of BP solved in corn oil by daily oral gavage at nine 
clock a.m. for 14 consecutive days. On day 15, the animals 
were weighed and sacrificed under ether anaesthesia, 
followed by decapitation. Tissue samples, liver, kidney, 
brain and testis were removed and stored at -80 °C until 
analysis.
Serum biochemistry
At the end of the experiment, all blood was taken from 
the heart of the rats with a sterile syringe and transferred to 
gel vacuum biochemistry tubes for serum analysis. Blood 
samples were then centrifuged at 500×g and 4 °C for 25 
min to separate the serum fraction, which was then placed 
in Eppendorf tubes and stored at -80 °C until ALT, AST, 
urea, triglyceride, glucose, creatinine, and albumin analysis 
with a Schimadzu clinical spectrophotometer CL-770 
(Kyoto, Japan) in the Toxicology Laboratory of Hacettepe 
University Department of Biology.
Histopathological analysis
Liver, kidney, testis, and brain samples of male rats were 
fixed in the Bouin’s solution for 8 h before histopathological 
examination. All tissues were embedded in the paraffin, and 
4 µm thick sections stained with Harris haematoxylin and 
eosin (H&E). All slides were inspected with an Olympus 
BX51 light microscope (200x magnification, (Tokyo, 
Japan). The photographs were processed with a Bs200prop 
software (BAB Imaging System, Ankara, Turkey).
Tissue preparation and evaluation of enzyme activity
All tissues were placed in ice-cold sterile physiological 
saline solution to wash out blood and then placed in liquid 
nitrogen.
 Samples for determination of enzyme activity and 
protein concentrations were homogenised with an Ultra 
Turrax homogeniser with a S18N-10G probe (IKA, 
Königswinter, Germany) and mixed in a 1:3 volume with 
50 mmol/L potassium phosphate buffer (pH 7.4) containing 
protease inhibitors. The homogenate was first centrifuged 
in a Beckman Coulter ultracentrifuge (Fullerton, CA, USA) 
at 105,000×g at 4 °C for 60 min, the pellet was removed, 
and the supernatants used to measure anti-oxidant enzyme 
activities with a LKB Ultraspec Plus spectrophotometer 
(4054 UV/visible, Biochrom Ltd., Cambridge, UK).
G6PD activity was measured according to the method 
described by Betke et al. (29) in a reaction mixture 
containing 0.6 mmol/L G6P and 100 mmol/L of Tris-HCl 
buffer (pH 8.0) containing 10 mmol/L MgCl2 and 
0.2 mmol/L NADP+. NADPH production was monitored 
at 340 nm at 37 °C for 60 s. Measurements were performed 
in duplicate, and one unit (U) of activity was defined as the 
amount of enzyme required to reduce one mmol NADP+/
min under the assay conditions. 6-phosphogluconate 
dehydrogenase activity (6PGD) was determined in the same 
way as above except that the mixture contained 0.6 mmol/L 
6PG as substrate instead of G6P (30).
Glutathione reductase activity was determined 
according to a modified Staal method (31). Decrease in the 
absorbance of NADPH at 340 nm was monitored 
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spectrophotometrically at 37 °C for 60 s. Unit of activity 
(U) was defined as the amount of enzyme needed to catalyse 
the oxidation of 1 µmol of NADPH in 1 min. Glutathione-
S-transferase (GST) activity was evaluated by the 
determining the conjugation of reduced glutathione (GSH) 
with 1-chloro-2,4-dinitrobenzene (CDNB) (32). The assay 
mixture consisted of 0.2 mol/L sodium phosphate buffer 
(pH 6.5), 20 mmol/L GSH, 20 mmol/L CDNB, 5 µL tissue 
homogenate, and double distilled water added to fill up the 
volume to 500 µL. Experiments were carried out in the 
duplicate, and activities followed for 30 s. Glutathione 
peroxidase (GPx) activity was measured according to 
Beutler et al (33). The assay mixture contained 100 mmol/L 
potassium phosphate buffer (pH 7.0), 200 mmol/L EDTA, 
GR enzyme (10 U/mL), 400 mmol/L sodium azide, 
100 mmol/L GSH, 2 mmol/L NADPH, 5 µL tissue lysate, 
and distilled water to fill up the volume to 500 µL. The 
mixture was incubated at 37 °C for 10 min and then 5 µL 
of 10 mmol/L H2O2 was added into the reaction mixture. 
The decrease in optical density (OD) of the system was 
measured at 340 nm at room temperature for 30 s. One unit 
of activity (U) was defined the same as above.
Protein concentration of tissue homogenates was 
determined with the bicinchoninic (BCA) method in 96-well 
plates using Spectramax M2 microplate reader (BioTek, 
Winooski, VT, USA) (34).
Statistical analysis
For statistical analysis we used the GraphPad Prism 
software (San Diego, CA, USA). All data were analysed 
with one-way analysis of variance (ANOVA) followed by 
a Tukey’s post hoc test for multiple comparison. The results 
were represented as mean ± standard deviation (SD).
RESULTS AND DISCUSSION
Animal weight, food and water consumption
Table 1 shows the differences in food and water 
consumption and weight gain between control and BP-
treated animal groups. Lower food consumption and 
correspondingly lower weight gain in BP-treated animals 
may point to adverse health effects of BP.
Tissue weight
Table 2 shows differences in tissue weights between 
animal groups. Liver weight in the 200 mg/kg/day dose group 
was significantly lower and in the 400 and 800 mg/kg/day 
dose groups significantly higher than in controls. The last 
two groups also had significantly higher kidney weight than 
controls. These increases are indicative of tissue damage 
(35–37), which was confirmed by histopathological findings 
below. However, BP treatment did not affect the weights 
of the brain and testis.
Serum biochemical parameters
Table 3 shows that BP treatment significantly affected 
only ALT and AST levels. Low ALT and AST levels indicate 
impaired liver function (36, 37), which was confirmed by 
our histopathology and antioxidant enzyme findings below 
(Figure 2, Table 5).
Antioxidant enzyme activities and histopathological 
confirmation
Tables 4–7 clearly show that BP significantly affected 
anti-oxidant enzyme activities in rat liver, kidney, brain, 
and testis compared to control. This is in line with the few 
Table 1 Food and water consumption of rats in the control and butylparaben-treated groups
Control
Butylparaben
200 mg/kg/day 400 mg/kg/day 800 mg/kg/day
Food consumption (g) 14.61±2.82 13.68±2.79 12.51±1.43a 13.88±1.66
Water consumption (ml) 30.3±6.82 28.07±5.36a 32.24±3.63 38.88±5.97a,b
Initial body weight (g) 141.83±19.67 147.83±10.14 183.83±13.59 188.83±7.29
Final body weight (g) 187±25.66 182.67±17.75 224.67±20.27 232±17.81
Weight gain (%) 31.39±11.83 23.52±7.63a 21.93±4.31a 22.74±6.1a
All results are given as mean±SD of six animals. asignificantly different from control (p≤0.05)
Table 2 Organ weight of rats in control and butylparaben-treated groups
Organ Control
Butylparaben
200 mg/kg/day 400 mg/kg/day 800 mg/kg/day
Brain (g) 1.50±0.06 1.59±0.08 1.73±0.04 1.72±0.05
Liver (g) 7.5 ±1.02 6.08±0.84a 8.02±1.13b 8.37±1.37a,b
Kidney (g) 1.44±0.22 1.31±0.18 1.56±0.19a 1.7±0.22a,b
Testis (g) 1.28±0.12 1.22±0.15 1.40±0.14 1.47±0.09
All results are given as mean±SD of six animals. asignificantly different from control; b significantly different from the 200 mg/kg/day 
dose group (p≤0.05)
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reports there are about BP-induced oxidative stress. The 
one by Shah and Verma (25) reported higher levels of 
oxidative stress enzymes GPx, GST, catalase (CAT), and 
superoxide dismutase (SOD) in mice liver. Samarasinghe 
et al. (26) have shown that parabens can induce oxidative 
stress in human spermatozoa. Schreiber et al. (27) reported 
that BP can impair oxidative stress metabolism in rat testis.
Furthermore, we have supported our results by 
histopathological findings indicating tissue damage (Figures 
1–4).
Consistent changes have also been reported earlier by 
Zhang et al. (38), who found that n-butylparaben induced 
male reproductive disorders via deregulation of oestradiol 
and oestrogen receptors, reduced the layers of germinal 
epithelium, and changed the structure of the seminiferous 
tubule. Other authors reported that BP administration led 
to the apoptosis of spermatogenic cells in prepubertal rats 
and to the impairment of the Sertoli cell vimentin filaments 
(38–40). Aubert et al. (41) suggested that tubular 
degeneration, tubular dilatation, and dead cells in the tubules 
found at the highest BP dose may have resulted from 
apoptosis to avoid irreversible DNA damage.
CONCLUSION
This is the first study to have investigated and clearly 
shown that BP can impair oxidative balance and cause 
damage across rat brain, kidney, and liver (in addition to 
the testis). These results are consistent with the degenerative 
role of butylparaben on the cellular level, as it impairs 
homeostasis and antioxidant defence.
Butyl 4-hydroxybenzoate may not be as safe as initially 
thought, as this chemical affects enzyme activity, cellular 
homeostasis, and key tissues. Our findings have pointed 
toward oxidative stress as a likely mechanism behind BP-
induced damage, which calls for further investigation.
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Figure 1 Photomicrographs showing hyperchromatic cells (marked with arrows) in the rat brain cortex of BP-treated groups (B – 200 
mg/kg/day; C and D – 400 mg/kg/day; E and F – 800 mg/kg/day) compared to control (A) (stained with H&E, 200x magnification)
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Figure 2 Photomicrographs showing congestion (*), necrosis (→), mononucleer cell infiltration (↔), and vacuolization (v) of male 
rat liver tissue of the BP-treated groups (B – 200 mg/kg/day; C and D – 400 mg/kg/day; E and F – 800 mg/kg/day) compared to control 
(A) (stained with H&E, 200x magnification)
Table 3 Serum biochemistry of control and butylparaben-treated groups
Serum biochemical parameters Control
Butylparaben
200 mg/kg/day 400 mg/kg/day 800 mg/kg/day
ALT (UI/I) 19.31±2.74 17.1±0.85 15.91±0.93* 17.05±1.05
AST (UI/I) 101.13±2.77 83.52±3.76 59.43±0.58* 60.8±0.42*
Glucose (mg/dL) 179.82±16.04 169.57±6.39 166.28±17.49 165.85±26.23
Albumin (g/dL) 2.78±0.14 2.75±0.23 2.9±0.17 2.96±0.11
Creatinine (mg/dL) 0.15±0.04 0.16±0.01 0.15±0.02 0.17±0.02
Triglycerides(mg/dL) 0.2±0.04 0.21±0.05 0.21±0.05 0.2±0.04
Urea (mg/dL) 7.37±1.32 7.68±1.43 8.01±1.39 8.07±1.39
All results are given as mean±SD of six animals. *significantly different from control (p≤0.05)
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Figure 3 Photomicrographs showing atrophic tubules (at), congestion (c), germinal cell debris (gcd), and damaged tubules (dt) in testis 
tissues of the BP-treated groups (B – 200 mg/kg/day; C and D – 400 mg/kg/day; E and F – 800 mg/kg/day) compared to control (A) 
(stained with H&E, 200x magnification)
Table 4 Brain antioxidant enzyme activities in control and butylparaben-treated rats
Brain Control
Butylparaben
200 mg/kg/day 400 mg/kg/day 800 mg/kg/day
Glucose-6-phosphate dehydrogenase 
(G6PD) 0.0561±0.008 0.0771±0.012 
a,b,c 0.1551±0.022 d,e 0.0968±0.010 f
6-phosphogluconate dehydrogenase 
(6PGD) 0.0235±0.007 0.0325±0.004 
f* 0.0654±0.012g,h 0.0415±0.003 i
Glutathione-S-transferase (GST) 2.066±0.323 0.9858±0.219 j,k,l 3.427±0.876 m,n 1.699±0.22
Glutathione reductase (GR) 0.0394±0.007 0.1297±0.023 o,p 0.1460±0.019 r,s 0.0670±0.007 t
Glutathione peroxidase (GPx) 0.0725±0.018 0.2066±0.083 u,v,w 0.6133±0.138 y,z 0.2755±0.065
All results are given as mean±SD of n=6 animals. a 200 mg/kg/day butylparaben dose group is different from control group (p=0.013); b 
200 mg/kg/day dose group is different from 400 mg/kg/day dose group (p<0.0001); c 200 mg/kg/day dose group is different from 800 mg/kg/day 
dose group (p=0.024); d 400 mg/kg/day dose group is different from control group (p<0.0001); e 400 mg/kg/day dose group is different 800 mg/kg/day 
group (p<0.0001); f 800 mg/kg/day dose group different from control group (p<0.0001); f* 200 mg/kg/day dose group is different from 400 mg/kg/day 
group (p<0.0001); g 400 mg/kg/day butylparaben dose group is different from control group (p<0.0001); h 400 mg/kg/day butylparaben dose 
group is different from 800 mg/kg/day dose group (p≤0.0001); i 800 mg/kg/day dose group is different from control group (p<0.0001); 
j200 mg/kg/day butylparaben dose group is different from control group (p<0.0001); k200 mg/kg/day dose group is different from the 
400 mg/kg/day dose group (p<0.0001); l 200 mg/kg/day dose group is different from 800 mg/kg/day dose group (p=0.014); m 400 mg/kg/day 
dose group is different from control group (p<0.0001); n 400 mg/kg/day dose group is different 800 mg/kg/day group (p<0.0001); o 200 mg/kg/
day butylparaben dose group is different from control group (p<0.0001); p 200 mg/kg/day dose group is different from 800 mg/kg/day dose group 
(p<0.0001); r 400 mg/kg/day dose group is different from control group (p=0.014); s 400 mg/kg/day dose group is different from 800 mg/kg/day dose 
group (p<0.0001); t 800 mg/kg/day dose group is different from control group (p<0.0001); u 200 mg/kg/day butylparaben dose group is different from 
control group (p<0.0001); v 200 mg/kg/day dose group is different from 400 mg/kg/day dose group (p<0.0001); w 200 mg/kg/day dose group is 
different from 800 mg/kg/day dose group (p=0.014); y 400 mg/kg/day dose group is different from control group (p<0.0001); z 400 mg/kg/day dose 
group is different 800 mg/kg/day group (p<0.0001)
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Figure 4 Photomicrographs of atrophic glomerulus (ag), congestion (c), enlargement of glomerular capsule (egc), tubular degeneration 
(td), and mononuclear cell infiltration (mci) in the kidney tissue the BP-treated groups (B – 200 mg/kg/day; C and D – 400 mg/kg/day; 
E and F – 800 mg/kg/day) compared to control (A) (stained with H&E, 200x magnification)
Table 5 Liver antioxidant enzyme activities in control and butylparaben-treated rats
Liver Control
Butylparaben
200 mg/kg/day 400 mg/kg/day 800 mg/kg/day
Glucose-6-phosphate dehydrogenase 





Glutathione-S-transferase (GST) 13.91±3.554 7.927±0.671e 8.481±2.602f 7.280±3.342g
Glutathione reductase (GR) 0.1583±0.021 0.0954±0.008h 0.1371±0.023i 0.1527±0.028j
Glutathione peroxidase (GPx) 0.2382±0.076 0.2222±0.070 0.3933±0.117k,l 0.3566±0.102
All results were given as mean ± SD of n=6 animals. a 400 mg/kg/day butylparaben dose group is different from 200 mg/kg/day group 
(p=0.038); b 200 mg/kg/day butylparaben dose group is different control group (p<0.0001); c 400 mg/kg/day dose group is different 
from control group (p=0.047); d 800 mg/kg/day dose group is different from control group (p=0.015), (p=0.021); e 200 mg/kg/day 
butylparaben dose group is different control group (p≤0.0001); f 400 mg/kg/day dose group is different from control group (p<0.0001); 
g 800 mg/kg/day dose group is different from control group (p<0.0001); h 200 mg/kg/day butylparaben dose group is different control 
group (p≤0.0001); i 400 mg/kg/day dose group is different from 200 mg/kg/day dose group (p<0.0001); j 800 mg/kg/day dose group 
is different from 200 mg/kg/day dose group (p<0.0001); k 400 mg/kg/day butylparaben dose group is different control group (p=0.031); 
l 400 mg/kg/day dose group is different from 200 mg/kg/day dose group (p=0.015)
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Table 6 Testis antioxidant enzyme activities in control and butylparaben-treated rats
Testis Control
Butylparaben







Glutathione-S-transferase (GST) 12.69±2.043 15.30±3.561k 11.9±1.853 13.42±2.314
Glutathione reductase (GR) 0.0215±0.003 0.0445±0.009l,m,n 0.0243±0.004 0.0355±0.005o,p
Glutathione peroxidase (GPx) 0.0764±0.007 0.0208±0.008r,s,t 0.0332±0.006u,v 0.0778±0.013
All results were given as mean ± SD of n=6 animals. a 200 mg/kg/day butylparaben dose group is different from control group (p<0.0001); 
b 400 mg/kg/day dose group is different from control group (p<0.0001); c 200 mg/kg/day dose group is different from 400 mg/kg/day 
dose group (p<0.0001); d 200 mg/kg/day dose group is different from 800 mg/kg/day dose group (p<0.0001); e 400 mg/kg/day dose 
group is different 800 mg/kg/day group (p<0.0001); f 200 mg/kg/day dose group is different from control group (p<0.0001); 
g 200 mg/kg/day butylparaben dose group is different from 400 mg/kg/day dose group (p<0.0001); h 200 mg/kg/day butylparaben dose 
group is different from 800 mg/kg/day dose group (p≤0.0001); i 400 mg/kg/day dose group is different from control group (p=0.013); 
j 400 mg/kg/day dose group is different from 800 mg/kg/day dose group (p=0.025); k 400 mg/kg/day butylparaben dose group is different 
from 200 mg/kg/day dose group (p=0.020); l 200 mg/kg/day dose group is different from control group (p<0.0001); 
m 200 mg/kg/day butylparaben dose group is different from 400 mg/kg/day dose group (p<0.0001); n 200 mg/kg/day butylparaben dose 
group is different from 800 mg/kg/day dose group (p=0.06); o 800 mg/kg/day dose group is different from control group (p<0.0001); 
p 800 mg/kg/day dose group is different from 400 mg/kg/day dose group (p=0.005); r 200 mg/kg/day dose group is different from 
control group (p<0.0001); s 200 mg/kg/day butylparaben dose group is different from 400 mg/kg/day dose group (p=0.240); 
t 200 mg/kg/day butylparaben dose group is different from 800 mg/kg/day dose group (p<0.0001); o 800 mg/kg/day dose group is 
different from control group (p<0.0001); p 800 mg/kg/day dose group is different from 400 mg/kg/day dose group (p=0.005); 
u 400 mg/kg/day butylparaben dose group is different from control group (p<0.0001); v 400 mg/kg/day dose group is different from 
800 mg/kg/day dose group (p<0.0001)
Table 7 Kidney antioxidant enzyme activities in control and butylparaben-treated rats
Kidney Control
Butylparaben







Glutathione-S-transferase (GST) 12.69±2.043 15.30±3.561k 11.9±1.853 13.42±2.314
Glutathione reductase (GR) 0.0215±0.003 0.0445±0.009l,m,n 0.0243±0.004 0.0355±0.005o,p
Glutathione peroxidase (GPx) 0.0764±0.007 0.0208±0.008r,s,t 0.0332±0.006u,v 0.0778±0.013
All results were given as mean ± SD of n=6 animals. a 200 mg/kg/day butylparaben dose group is different from control group (p<0.0001); 
b 400 mg/kg/day dose group is different from control group (p<0.0001); c 200 mg/kg/day dose group is different from 400 mg/kg/day 
dose group (p<0.0001); d 200 mg/kg/day dose group is different from 800 mg/kg/day dose group (p<0.0001); e 400 mg/kg/day dose 
group is different 800 mg/kg/day group (p<0.0001); f 200 mg/kg/day dose group is different from control group (p<0.0001); 
g 200 mg/kg/day butylparaben dose group is different from 400 mg/kg/day dose group (p<0.0001); h 200 mg/kg/day butylparaben dose 
group is different from 800 mg/kg/day dose group (p≤0.0001); i 400 mg/kg/day dose group is different from control group (p=0.013); 
j 400 mg/kg/day dose group is different from 800 mg/kg/day dose group (p=0.025); k 400 mg/kg/day butylparaben dose group is different 
from 200 mg/kg/day dose group (p=0.020); l 200 mg/kg/day dose group is different from control group (p<0.0001); m 200 mg/kg/day 
butylparaben dose group is different from 400 mg/kg/day dose group (p<0.0001); n 200 mg/kg/day butylparaben dose group is different 
from 800 mg/kg/day dose group (p=0.06); o 800 mg/kg/day dose group is different from control group (p<0.0001); p 800 mg/kg/day 
dose group is different from 400 mg/kg/day dose group (p=0.005); r 200 mg/kg/day dose group is different from control group (p<0.0001); 
s 200 mg/kg/day butylparaben dose group is different from 400 mg/kg/day dose group (p=0.240); t 200 mg/kg/day butylparaben dose 
group is different from 800 mg/kg/day dose group (p<0.0001); o 800 mg/kg/day dose group is different from control group (p<0.0001); 
p 800 mg/kg/day dose group is different from 400 mg/kg/day dose group (p=0.005); u 400 mg/kg/day butylparaben dose group is 
different from control group (p<0.0001); v 400 mg/kg/day dose group is different from 800 mg/kg/day dose group (p<0.0001)
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Djelovanje butilparabena na aktivnost antioksidacijskih enzima i histopatološke promjene u tkivima štakora
Butil p-hidroksibenzoična kiselina, poznata i pod nazivom butilparaben (BP), najčešći je oblik parabena, koji se apsorbira 
putem kože i probavnoga sustava te razgrađuje u jetri i bubrezima. Najnovija istraživanja in vivo i in vitro upozoravaju 
na to da BP djeluje toksično na reproduktivne organe, plod (teratogeno djelovanje) i razvoj organizma. No dosad nije 
detaljno istražen oksidacijski stres koji on izaziva niti njegova povezanost s oštećenjem tkiva. Stoga je cilj ovoga istraživanja 
bio utvrditi djelovanje BP-a na aktivnost enzima koji sudjeluju u pentoza fosfatnom putu i onih ovisnih o glutationu poput 
glukoza-6-fosfat dehidrogenaze (G6PD), 6-fosfoglukonat dehidrogenaze (6-PGD), glutation reduktaze (GR), glutation 
peroksidaze (GPx) i glutation-S-transferaze (GST) u tkivu bubrega, jetre, mozga i testisa. U tu su svrhu muški štakori bili 
nasumce raspodijeljeni u četiri skupine: tri su skupine četrnaest dana primale oralne doze BP-a od 200, 400 ili 800 mg/kg 
na dan, a kontrolna skupina kukuruzno ulje. Nakon tretmana životinje su žrtvovane i u njihovim su tkivima izmjerene 
aktivnosti G6PD, GR, GST, 6-PGD i GPx te su napravljene histopatološke pretrage tkiva. BP je poremetio ravnotežu 
enzimskih aktivnosti te doveo do oštećenja svih ispitanih vrsta tkiva. Ovo su prvi nalazi koji potvrđuju degenerativnu 
ulogu BP-a na staničnoj razini. Zabilježeni poremećaji homeostaze i obrambenoga antioksidacijskoga sustava upućuju 
na oksidacijski stres kao mehanizam u podlozi oštećenja tkiva izazvanoga BP-om.
KLJUČNE RIJEČI: endokrini disruptori, glukoza-6-fosfat dehidrogenaza; 6-fosfoglukonat dehidrogenaza; glutation 
peroksidaza; glutation reduktaza; glutation-S-transferaza
